AGEN

SEC source: 0000899243-21-027315 · doc4.xml · derivative · entry 1

Corvese Brian · CIK 0001393207 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2030-12-17

F1 · derivative.exercise_date: Option was granted on January 1, 2021, subject to shareholder approval of an increase to the available pool under the Company's 2019 Equity Incentive Plan ("2019 Plan"), which was obtained at the Company's annual shareholder meeting on June 15, 2021. Option awarded in accordance with the 2019 Plan. Option vests in full on December 17, 2022.

SEC source: 0000899243-21-027304 · doc4.xml · derivative · entry 1

Krauss Adam · CIK 0001836505 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 175,000

Underlying: Common Stock · 175,000 shares

Expires 2030-12-17

F1 · derivative.exercise_date: Option was granted on January 1, 2021, subject to shareholder approval of an increase to the available pool under the Company's 2019 Equity Incentive Plan ("2019 Plan"), which was obtained at the Company's annual shareholder meeting on June 15, 2021. Option awarded in accordance with the 2019 Plan. Option vests over a four-year period, with 1/3 of Option vesting on December 17, 2022, and the balance vesting in eight equal quarterly installments thereafter.

SEC source: 0000899243-21-027312 · doc4.xml · derivative · entry 1

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2030-12-17

F1 · derivative.exercise_date: Option was granted on January 1, 2021, subject to shareholder approval of an increase to the available pool under the Company's 2019 Equity Incentive Plan ("2019 Plan"), which was obtained at the Company's annual shareholder meeting on June 15, 2021. Option awarded in accordance with the 2019 Plan. Option vests in full on December 17, 2022.

SEC source: 0000899243-21-027297 · doc4.xml · derivative · entry 1

Jeynes-Ellis Allison M · CIK 0001758521 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2030-12-17

F1 · derivative.exercise_date: Option was granted on January 1, 2021, subject to shareholder approval of an increase to the available pool under the Company's 2019 Equity Incentive Plan ("2019 Plan"), which was obtained at the Company's annual shareholder meeting on June 15, 2021. Option awarded in accordance with the 2019 Plan. Option vests in full on December 17, 2022.

SEC source: 0000899243-21-027301 · doc4.xml · derivative · entry 1

Wright Timothy · CIK 0001383313 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2030-12-17

F1 · derivative.exercise_date: Option was granted on January 1, 2021, subject to shareholder approval of an increase to the available pool under the Company's 2019 Equity Incentive Plan ("2019 Plan"), which was obtained at the Company's annual shareholder meeting on June 15, 2021. Option awarded in accordance with the 2019 Plan. Option vests in full on December 17, 2022.

SEC source: 0000899243-21-027295 · doc4.xml · derivative · entry 1

JORDAN WADIH · CIK 0001222090 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2030-12-17

F1 · derivative.exercise_date: Option was granted on January 1, 2021, subject to shareholder approval of an increase to the available pool under the Company's 2019 Equity Incentive Plan ("2019 Plan"), which was obtained at the Company's annual shareholder meeting on June 15, 2021. Option awarded in accordance with the 2019 Plan. Option vests in full on December 17, 2022.

SEC source: 0000899243-21-022383 · doc4.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 607,211

F1 · security: As previously reported in the Current Report on Form 8-K filed with the Securities and Exchange Commission on January 14, 2021, Garo H. Armen's salary is being paid in stock, in lieu of cash, for the first half of 2021. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending June 4, 2021. Such shares are issued in accordance with the Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F2 · price: $4.03 is the closing price of our Common Stock on June 4, 2021, the payroll date for the pay period ending June 4, 2021.

SEC source: 0000899243-21-020399 · doc4.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 603,541

F1 · security: As previously reported in the Current Report on Form 8-K filed with the Securities and Exchange Commission on January 14, 2021, Garo H. Armen's salary is being paid in stock, in lieu of cash, for the first half of 2021. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending May 21, 2021. Such shares are issued in accordance with the Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F2 · price: $4.19 is the closing price of our Common Stock on May 21, 2021, the payroll date for the pay period ending May 21, 2021.

SEC source: 0000899243-21-018729 · doc4.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 600,011

F1 · security: As previously reported in the Current Report on Form 8-K filed with the Securities and Exchange Commission on January 14, 2021, Garo H. Armen's salary is being paid in stock, in lieu of cash, for the first half of 2021. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending May 7, 2021. Such shares are issued in accordance with the Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F2 · price: $3.07 is the closing price of our Common Stock on May 7, 2021, the payroll date for the pay period ending May 7, 2021.

SEC source: 0001745285-21-000019 · primary_doc.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 595,194

F1 · security: As previously reported in Current Report on Form 8-K filed with the Securities and Exchange Commission on January 14, 2021, Garo H. Armen's salary is being paid in stock, in lieu of cash, for the first half of 2021. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending April 23, 2021. Such shares are issued in accordance with the Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F2 · price: $3.05 is the closing price of our Common Stock on April 23, 2021, the payroll date for the pay period ending April 23, 2021.

SEC source: 0001745285-21-000018 · primary_doc.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 590,345

F1 · security: As previously reported in Current Report on Form 8-K filed with the Securities and Exchange Commission on January 14, 2021, Garo H. Armen's salary is being paid in stock, in lieu of cash, for the first half of 2021. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending April 9, 2021. Such shares are issued in accordance with the Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F2 · price: $2.785 is the closing price of our Common Stock on April 9, 2021, the payroll date for the pay period ending April 9, 2021.

SEC source: 0000899243-21-014724 · doc4.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 585,700

F1 · security: All Agenus employees were given the option to receive their 2020 bonus awards in cash or Agenus stock. Dr. Armen, Dr. Buell and Ms. Klaskin have all chosen to receive their entire 2020 bonus award in Agenus stock rather than cash. The stock issued is fully-vested on the date of issuance, but is subject to a 6-month lockup restriction. In addition, Dr. Armen continues to receive his base salary in Agenus stock rather than cash

F2 · price: $2.87 is the fair market value of our Common Stock on April 2, 2021, the stock issuance date.

SEC source: 0000899243-21-014727 · doc4.xml · nonDerivative · entry 1

Buell Jennifer · CIK 0001711184 · President & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 116,494

F1 · security: All Agenus employees were given the option to receive their 2020 bonus awards in cash or Agenus stock. Dr. Armen, Dr. Buell and Ms. Klaskin have all chosen to receive their entire 2020 bonus award in Agenus stock rather than cash. The stock issued is fully-vested on the date of issuance, but is subject to a 6-month lockup restriction.

F2 · price: $2.87 is the fair market value of our Common Stock on April 2, 2021, the stock issuance date.

SEC source: 0000899243-21-014725 · doc4.xml · nonDerivative · entry 1

KLASKIN CHRISTINE M · CIK 0001288123 · PFO & PAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 88,611

F1 · security: All Agenus employees were given the option to receive their 2020 bonus awards in cash or Agenus stock. Dr. Armen, Dr. Buell and Ms. Klaskin have all chosen to receive their entire 2020 bonus award in Agenus stock rather than cash. The stock issued is fully-vested on the date of issuance, but is subject to a 6-month lockup restriction.

F2 · price: $2.87 is the fair market value of our Common Stock on April 2, 2021, the stock issuance date.

SEC source: 0001745285-21-000017 · primary_doc.xml · nonDerivative · entry 1

Hirsch Susan B · CIK 0001827663 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,729

F1 · security: Acquired under the Agenus Inc. Board Compensation Election Policy pursuant to which a director may elect to receive her director fees in shares of Agenus' common stock.

F2 · price: $3.682 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such shares were issued.

SEC source: 0001745285-21-000016 · primary_doc.xml · derivative · entry 1

Wright Timothy · CIK 0001383313 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 128,474.452

Underlying: Common Stock · 2,546.307 shares

Expires not disclosed

F1 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis.

F3 · price: $3.682 per Deferred Stock Unit acquired on April 1, 2021. The price of each Deferred Stock Unit acquired prior to April 1, 2021 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan.

F2 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

F2 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

SEC source: 0001745285-21-000014 · primary_doc.xml · derivative · entry 1

JORDAN WADIH · CIK 0001222090 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 188,135.329

Underlying: Common Stock · 7,129.658 shares

Expires not disclosed

F1 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis.

F3 · price: $3.682 per Deferred Stock Unit acquired on April 1, 2021. The price of each Deferred Stock Unit acquired prior to April 1, 2021 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan.

F2 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

F2 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

SEC source: 0001745285-21-000015 · primary_doc.xml · derivative · entry 1

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 110,098.9

Underlying: Common Stock · 6,959.905 shares

Expires not disclosed

F1 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis.

F3 · price: $3.682 per Deferred Stock Unit acquired on April 1, 2021. The price of each Deferred Stock Unit acquired prior to April 1, 2021 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan.

F2 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

F2 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

SEC source: 0001745285-21-000013 · primary_doc.xml · derivative · entry 1

CLARK PAUL N · CIK 0001222248 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,092.613

Underlying: Common Stock · 5,092.613 shares

Expires not disclosed

F1 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis.

F3 · price: $3.682 per Deferred Stock Unit acquired on April 1, 2021.

F2 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

F2 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

SEC source: 0001745285-21-000012 · primary_doc.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 449,922

F1 · security: As previously reported in the Current Report on Form 8-K filed with the Securities and Exchange Commission on January 14, 2021, Garo H. Armen's salary is being paid in stock, in lieu of cash, for the first half of 2021. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending March 26, 2021. Such shares are issued in accordance with the Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F2 · price: $2.85 is the closing price of our Common Stock on March 26, 2021, the payroll date for the pay period ending March 26, 2021.

SEC source: 0001745285-21-000011 · primary_doc.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 445,745

F1 · security: As previously reported in the Current Report on Form 8-K filed with the Securities and Exchange Commission on January 14, 2021, Garo H. Armen's salary is being paid in stock, in lieu of cash, for the first half of 2021. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending March 12, 2021. Such shares are issued in accordance with the Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F2 · price: $3.31 is the closing price of our Common Stock on March 12, 2021, the payroll date for the pay period ending March 12, 2021.

SEC source: 0001745285-21-000010 · primary_doc.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 442,317

F1 · security: As previously reported in the Current Report on Form 8-K filed with the Securities and Exchange Commission on January 14, 2021, Garo H. Armen's salary is being paid in stock, in lieu of cash, for the first half of 2021. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending February 26, 2021. Such shares are issued in accordance with the Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F2 · price: $4.00 is the closing price of our Common Stock on February 26, 2021, the payroll date for the pay period ending February 26, 2021.

SEC source: 0001745285-21-000009 · primary_doc.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 439,481

F1 · security: As previously reported in the Current Report on Form 8-K filed with the Securities and Exchange Commission on January 14, 2021, Garo H. Armen's salary is being paid in stock, in lieu of cash, for the first half of 2021. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending February 12, 2021. Such shares are issued in accordance with the Agenus Inc. 2019 Equity Incentive Plan as are fully vested on the date of issuance.

F2 · price: $4.64 is the closing price of our Common Stock on February 12, 2021, the payroll date for the pay period ending February 12, 2021.

SEC source: 0001745285-21-000008 · primary_doc.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 437,036

F1 · security: As previously reported in the Current Report on Form 8-K filed with the Securities and Exchange Commission on January 14, 2021, Garo H. Armen's salary is being paid in stock, in lieu of cash, for the first half of 2021. The amount represented herein represents the net amount of Dr. Armen's salary for the pay period ending January 29, 2021. Such shares are issued in accordance with the Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F2 · price: $3.68 is the closing price of our Common Stock on January 29, 2021, the payroll date for the pay period ending January 29, 2021.

SEC source: 0001745285-21-000007 · primary_doc.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 433,953

F1 · security: As previously reported in the Current Report on Form 8-K filed with the Securities and Exchange Commission on January 14, 2021, Garo H. Armen's salary is being paid in stock, in lieu of cash, for the first half of 2021. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending January 15, 2021. Such shares are issued in accordance with the Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F2 · price: $3.35 is the closing price of our Common Stock on January 15, 2021, the payroll date for the pay period ending January 15, 2021.

SEC source: 0001745285-21-000006 · primary_doc.xml · nonDerivative · entry 1

Hirsch Susan B · CIK 0001827663 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,637

F1 · security: Acquired under the Agenus Inc. Board Compensation Election Policy pursuant to which a director may elect to receive her director fees in shares of Agenus' common stock.

F2 · price: $3.78 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such shares were issued.

SEC source: 0001745285-21-000005 · primary_doc.xml · derivative · entry 1

JORDAN WADIH · CIK 0001222090 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 181,005.671

Underlying: Common Stock · 5,620.996 shares

Expires not disclosed

F1 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis.

F3 · price: $3.780 per Deferred Stock Unit acquired on January 4, 2021. The price of each Deferred Stock Unit acquired prior to January 4, 2021 is the average of the closing price for the Company's Common Stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan.

F2 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's Common Stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

F2 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's Common Stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

SEC source: 0001745285-21-000004 · primary_doc.xml · derivative · entry 1

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 96,179.09

Underlying: Common Stock · 5,896.535 shares

Expires not disclosed

F1 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis.

F3 · price: $3.780 per Deferred Stock Unit acquired on January 4, 2021. The price of each Deferred Stock Unit acquire prior to January 4, 2021 is the average of the closing price for the Company's Common Stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan.

F2 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's Common Stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

F2 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's Common Stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

SEC source: 0001745285-21-000003 · primary_doc.xml · derivative · entry 1

Wright Timothy · CIK 0001383313 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,928.145

Underlying: Common Stock · 2,149.204 shares

Expires not disclosed

F1 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis.

F3 · price: $3.780 per Deferred Stock Unit acquired on January 4, 2021. The price of each Deferred Stock Unit acquired prior to January 4, 2021 is the average of the closing price for the Company's Common Stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan.

F2 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's Common Stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

F2 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's Common Stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

SEC source: 0001745285-21-000001 · primary_doc.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 430,538

F1 · security: As previously reported in Current Report on Form 8-K filed with the Securities and Exchange Commission on March 30, 2020, Garo H. Armen's salary is being paid in stock, in lieu of cash, for the balance of 2020. The amount reported herein represents the net amount of Dr. Armen's salary for the period ending December 31, 2020. Such shares are issued in accordance with the Agenus Inc. 2019 Equity Incentive Plan (the "2019 Plan") and are fully vested on the date of issuance.

F2 · price: $3.18 is the closing price of our Common Stock on December 31, 2020, the payroll date for the pay period ending December 31, 2020.

SEC source: 0001745285-21-000002 · primary_doc.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 430,567

F1 · security: As previously reported in Current Report on Form 8-K FILED with the Securities and Exchange Commission on March 30, 2020, Garo H. Armen's salary is being paid in stock, in lieu of cash, for the balance of 2020. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending December 31, 2020. Such shares are issued in accordance with the Agenus 2019 Equity Incentive Plan (the "2019 Plan") and are fully vested on the date of issuance.

F2 · price: $3.18 is the closing price of our Common Stock on December 31, 2020, the payroll date for the pay period ending December 31, 2020.

SEC source: 0001745285-20-000043 · primary_doc.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 421,845

F1 · security: As previously reported in Current Report on Form 8-K filed with the Securities and Exchange Commission on March 30, 2020, Garo H. Armen's salary is being paid in stock, in lieu of cash, for the balance of 2020. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending December 18, 2020. Such shares are issued in accordance with the Agenus Inc. 2019 Equity Incentive Plan (the "2019 Plan") and are fully vested on the date of issuance.

F2 · price: $3.55 is the closing price of our Common Stock on December 18, 2020, the payroll date for the pay period ending December 18, 2020.

SEC source: 0001745285-20-000043 · primary_doc.xml · derivative · entry 4

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,900,000

Underlying: Common Stock · 1,900,000 shares

Expires 2030-12-17

F5 · derivative.exercise_date: Stock Option awarded in accordance with the 2019 Plan. One-third of the Stock Option vests on December 17, 2021, with the remaining vesting in eight equal quarterly installments thereafter; provided Dr. Armen maintains a service relationship with the Company through each such vesting date and in the event of Dr. Armen's death, disability or retirement, all of the unvested options will vest in full and become exercisable, and each stock option will remain exercisable for the lesser of (a) three years from the date of such event or (b) the end of the 10-year term of each such stock option.

SEC source: 0001745285-20-000052 · primary_doc.xml · derivative · entry 1

Wright Timothy · CIK 0001383313 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2030-12-17

F1 · derivative.exercise_date: Stock Option awarded in accordance with the Agenus Inc. 2019 Equity Incentive Plan. The Stock Option vests in full on December 17, 2021 (provided Mr. Wright continues to serve on the board on such date).

SEC source: 0001745285-20-000051 · primary_doc.xml · derivative · entry 1

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2030-12-17

F1 · derivative.exercise_date: Stock Option awarded in accordance with the Agenus Inc. 2019 Equity Incentive Plan. The Stock Option vests in full on December 17, 2021 (provided Mr. Wiinberg continues to serve on the board on such date).

SEC source: 0001745285-20-000050 · primary_doc.xml · derivative · entry 1

JORDAN WADIH · CIK 0001222090 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2030-12-17

F1 · derivative.exercise_date: Stock Option awarded in accordance with the Agenus Inc. 2019 Equity Incentive Plan. The Stock Option vests in full on December 17, 2021 (provided Mr. Jordan continues to serve on the board on such date).

SEC source: 0001745285-20-000049 · primary_doc.xml · derivative · entry 1

Jeynes-Ellis Allison M · CIK 0001758521 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2030-12-17

F1 · derivative.exercise_date: Stock Option awarded in accordance with the Agenus Inc. 2019 Equity Incentive Plan. The Stock Option vests in full on December 17, 2021 (provided Dr. Jeynes-Ellis continues to serve on the board on such date).

SEC source: 0001745285-20-000048 · primary_doc.xml · derivative · entry 1

Hirsch Susan B · CIK 0001827663 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2030-12-17

F1 · derivative.exercise_date: Stock Option awarded in accordance with the Agenus Inc. 2019 Equity Incentive Plan. The Stock Option vests in full on December 17, 2021 (provided Ms. Hirsch continues to serve on the board on such date).

SEC source: 0001745285-20-000047 · primary_doc.xml · derivative · entry 1

Corvese Brian · CIK 0001393207 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2030-12-17

F1 · derivative.exercise_date: Stock Option awarded in accordance with the Agenus Inc. 2019 Equity Incentive Plan. The Stock Option vests in full on December 17, 2021 (provided Mr. Corvese continues to serve on the board on such date).

SEC source: 0001745285-20-000046 · primary_doc.xml · derivative · entry 1

CLARK PAUL N · CIK 0001222248 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2030-12-17

F1 · derivative.exercise_date: Stock Option awarded in accordance with the Agenus Inc. 2019 Equity Incentive Plan. The Stock Option vests in full on December 17, 2021 (provided Mr. Clark continues to serve on the board on such date).

SEC source: 0000899243-20-034670 · doc4.xml · derivative · entry 1

Krauss Adam · CIK 0001836505 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2030-12-17

F1 · derivative.exercise_date: Stock Option awarded in accordance with the Agenus Inc. 2019 Equity Incentive Plan. One-third of the Stock Option vests on December 17, 2021, with the remaining vesting in eight equal quarterly installments thereafter (provided Mr. Krauss maintains a service relationship with the Company through each such vesting date).

SEC source: 0001745285-20-000045 · primary_doc.xml · derivative · entry 1

Kearns Evan · CIK 0001745285 · VP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2030-12-17

F1 · derivative.exercise_date: Stock Option awarded in accordance with the Agenus Inc. 2019 Equity Incentive Plan. One-third of the Stock Option vests on December 17, 2021, with the remaining vesting in eight equal quarterly installments thereafter (provided Mr. Kearns maintains a service relationship with the Company through each such vesting date).

SEC source: 0001745285-20-000044 · primary_doc.xml · derivative · entry 1

KLASKIN CHRISTINE M · CIK 0001288123 · PFO and PAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2030-12-17

F1 · derivative.exercise_date: Stock Option awarded in accordance with the Agenus Inc. 2019 Equity Incentive Plan. One-third of the Stock Option vests on December 17, 2021, with the remaining vesting in eight equal quarterly installments thereafter (provide Ms. Klaskin maintains a service relationship with the Company through each such vesting date).

SEC source: 0001745285-20-000042 · primary_doc.xml · derivative · entry 1

Buell Jennifer · CIK 0001711184 · COO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 900,000

Underlying: Common Stock · 900,000 shares

Expires 2030-12-17

F1 · derivative.exercise_date: Stock Option awarded in accordance with the Agenus Inc. 2019 Equity Incentive Plan. One-third of the Stock Option vests on December 17, 2021, with the remaining vesting in eight equal quarterly installments thereafter (provided Dr. Buell maintains a service relationship with the Company through each such vesting date).

SEC source: 0001745285-20-000041 · primary_doc.xml · nonDerivative · entry 3

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 417,682

F4 · security: As previously reported in Current Report on Form 8-K filed with the Securities and Exchange Commission on March 30, 2020, Garo H. Armen's salary is being paid in stock, in lieu of cash, for the balance of 2020. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending December 4, 2020. Such shares are issued in accordance with the Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F5 · price: $3.33 is the closing price of our Common Stock on December 4, 2020, the payroll date for the pay period ending December 4, 2020.

SEC source: 0001745285-20-000041 · primary_doc.xml · nonDerivative · entry 2

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote.

Disclosed balance after: 704,046

F3 · security: Distribution from the Garo Armen 2018 2 Year AG GRAT to the beneficiaries of the remainder interest. This transaction does not represent a sale of Agenus Common Stock.

F7 · ownership.nature: Dr. Armen is trustee and has investment authority for the Garo Armen 2020 2 Year AG GRAT holder of 600,000 shares of our Common Stock. Dr. Armen is Chairman of the Board of Managers and a member of Antigenics LLC ("Antigenics") which as of the date of this report owns 4,046 shares of our Common Stock. Dr. Armen is a general partner in Pixie Partners, a General Partnership ("Pixie"), which as of the date of this report owns 100,000 shares of our Common Stock. Dr. Armen has a pecuniary interest in only a portion of the shares held by Antigenics and Pixie and disclaims beneficial ownership to the extent of his pecuniary interest therein.

SEC source: 0001745285-20-000041 · primary_doc.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote.

Disclosed balance after: 735,146

F1 · security: Distribution from the Garo Armen 2018 2 Year AG GRAT to the beneficiaries of the remainder interest. This transaction does not represent a sale of Agenus Common Stock.

F2 · ownership.nature: Dr. Armen is trustee and has investment authority for the Garo Armen 2018 2 Year AG GRAT, which after this transaction was the holder of 31,100 shares of our Common Stock.

F7 · ownership.nature: Dr. Armen is trustee and has investment authority for the Garo Armen 2020 2 Year AG GRAT holder of 600,000 shares of our Common Stock. Dr. Armen is Chairman of the Board of Managers and a member of Antigenics LLC ("Antigenics") which as of the date of this report owns 4,046 shares of our Common Stock. Dr. Armen is a general partner in Pixie Partners, a General Partnership ("Pixie"), which as of the date of this report owns 100,000 shares of our Common Stock. Dr. Armen has a pecuniary interest in only a portion of the shares held by Antigenics and Pixie and disclaims beneficial ownership to the extent of his pecuniary interest therein.

SEC source: 0001745285-20-000040 · primary_doc.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 412,645

F1 · security: As previously reported in Current Report on Form 8-K filed with the Securities and Exchange Commission on March 30, 2020, Garo H. Armen's salary is being paid in stock, in lieu of cash, for the balance of 2020. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending November 20, 2020. Such shares are issued in accordance with the Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F2 · price: $3.65 is the closing price of our Common Stock on November 20, 2020, the payroll date for the pay period ending November 20, 2020.

SEC source: 0001745285-20-000039 · primary_doc.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 343,496

F1 · security: As previously reported in Current Report on Form 8-K filed with the Securities and Exchange Commission on March 30, 2020, Garo H. Armen's salary is being paid in stock, in lieu of cash, for the balance of 2020. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending November 6, 2020. Such shares are issued in accordance with the Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F2 · price: $3.82 is the closing price of our Common Stock on November 6, 2020, the payroll date for the pay period ending November 6, 2020.

SEC source: 0001745285-20-000038 · primary_doc.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 339,627

F1 · security: As previously reported in Current Report on Form 8-K filed with the Securities and Exchange Commission on March 30, 2020, Garo H. Armen's salary is being paid in stock, in lieu of cash, for the balance of 2020. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending October 23, 2020. Such shares are issued in accordance with the Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F2 · price: $3.94 is the closing price of our Common Stock on October 23, 2020, the payroll date for the pay period ending October 23, 2020.